Pfizer has been given a "Neutral" rating by UBS, with a price target of $31, according to analyst Trung Huynh. Despite a mixed performance this year, the pharmaceutical company is starting to regain investor confidence.
The report, published on November 14, 2024, acknowledges the ongoing challenges faced by Pfizer but suggests a potential turnaround as market sentiment improves. It is advised that investors closely monitor developments as the company works towards its recovery.